Neuphoria Therapeutics Inc.
NEUPNASDAQHealthcare● Active
$4.67
+$0.18(+4.01%)
Market Cap$25239253
P/E Ratio—
52W High$21.4
52W Low$3.645
Neuphoria Therapeutics Inc. (NEUP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NEUP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $15.65M | $0.00M | $0.00M | $0.38M | $0.00M |
| Cost of Revenue | $0.00M | $0.66M | $0.67M | $16.00M | $0.00M |
| Gross Profit | $15.65M | ($0.66M) | ($0.67M) | $0.38M | $0.00M |
| Gross Margin %(computed) | 100.00% | — | — | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $9.01M | $14.10M | $19.67M | $23.25M | $4.33M |
| G&A Expenses | $7.77M | $12.69M | $13.41M | $11.13M | $4.24M |
| Total Operating Expenses | $16.78M | $26.79M | $33.09M | $31.40M | $8.96M |
| Operating Income | ($1.13M) | ($26.79M) | ($33.09M) | ($31.02M) | ($8.96M) |
| Operating Margin %(computed) | -7.21% | — | — | — | — |
| Interest Income | $0.17M | $0.22M | $0.32M | $0.01M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.03M | $0.03M | $1.08M |
| Income Before Tax | ($0.84M) | ($23.32M) | ($32.39M) | ($31.90M) | ($6.68M) |
| Income Tax Expense | ($0.47M) | ($0.13M) | ($0.21M) | ($0.28M) | ($0.14M) |
| Net Income | ($0.37M) | ($23.19M) | ($32.18M) | ($31.62M) | ($6.53M) |
| Net Margin %(computed) | -2.36% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.23 | $-0.10 | $-0.18 | $-0.20 | $-0.10 |
| Wtd Avg Shares | 1.62M | 149.80M | 122.39M | 112.78M | 65.00M |
| EBITDA | ($0.12M) | ($25.65M) | ($31.45M) | ($30.25M) | ($4.51M) |
| EBITDA Margin %(computed) | -0.78% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Neuphoria Therapeutics Inc. data
About Neuphoria Therapeutics Inc. (NEUP) Income Statement
Neuphoria Therapeutics Inc. (NEUP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NEUP reported revenue of $0.02B, gross profit of $0.02B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -2.36%.
Frequently asked questions
NEUP · 4 questionsNeuphoria Therapeutics Inc. (NEUP) reported revenue of $0.02B for 2025, up —% year-over-year.
NEUP revenueNEUP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09